Last mentioned: Feb 26, 2026
Functional Cure Declared
Medical reports confirm the patient is effectively cured of the rare disease.
Long-term Follow-up
B.C. patient reports zero attacks one year after single dose.
Phase 1/2 Results
Intellia releases early data showing significant reduction in HAE attacks.
The Q4 2025 earnings reports from leading biotech and specialty pharma firms reveal a sector-wide transition toward commercial-stage CRISPR therapies and high-growth radiopharmaceuticals. Key players like Intellia and Lantheus are setting the pace for 2026, while specialty firms focus on operational efficiency and non-opioid alternatives.
A British Columbia man has been declared functionally cured of Hereditary Angioedema (HAE) following a world-first in-vivo CRISPR gene-editing treatment. The success of Intellia Therapeutics' NTLA-2002 therapy marks a pivotal shift from chronic disease management to permanent genetic correction.
This page surfaces every story mentioning Intellia Therapeutics across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Intellia Therapeutics was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |